Paul Feuerstadt, MD: RBX2660 and FMT for C Difficile Infections

October 25, 2021
Kenny Walter

Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.

It can be challenging to find a suitable donor for fecal microbiota transplantation.

While effective for treating Clostridioides difficile infections (CDI), it can be a challenge to find suitable donors for fecal microbiota transplantation (FMT).

Fecal microbiota transplantation is a procedure where healthy donor stool is infused to rectify the recipient’s intestinal microbial community by introducing micro-organisms associated with a health state to normalize microbiota composition and function.

There are plenty of reasons why potential FMT donors are ultimately rejected, including inability to come back for regular and long-term donation, high body mass index, underlying chronic illness or on long-term medications , being healthcare professionals, and the use of antibiotics within 3 months.

However, RBX2660 could be a viable option that does not rely on donor stool.

In data presenting at the 2021 American College of Gastroenterology (ACG) Annual Meeting, investigators found high clinical efficacy in reducing rCDI with a sustained clinical response up to 6 months, with consistent safety results from previous clinical trials.

In an interview with HCPLive®, Paul Feuerstadt , MD, Yale University School of Medicine, explained why RBX2660, if approved, would be a viable alternative to FMT.

Feuerstadt also discussed what the next steps are in studying the safety and efficacy of RBX2660.


x